NEJM: Preclinical study of COVID-19 candidate vaccine mRNA-1273: The effect is obvious!
-
Last Update: 2020-07-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- biotech company Moderna is a pioneer in messenger RNA (mRNA) therapeutics and vaccines, and Moderna today published a preclinical study to evaluate the COVID-19 candidate vaccine mRNA-1273, the results of which were published in NEJMThis study shows that in non-human primates, mRNA-1273 leads to a powerful immune response to SARS-CoV-2, which is protective of lower respiratory tract infectionsIn this study, non-human primates were evaluated for immunogenicity and protective effects every 4 weeks after being vaccinated at a dose of mRNA-1273 or a control vaccine at a dose of 10 ?g or 100 ?g., n.24; 8 per groupFour weeks after the second vaccination, animals were attacked with high doses of SARS-CoV-2 virus through the nasal and trachea pathwaysAt a dose of 10 ?g, the geometric mean titration (GMT, ID50) measured in the pseudovirus (PsV) and assays was 103, similar to the GMT (109) of a previously reported set of recovery-period serumsAt a dose of 100 ?g, neutralizing antibody titer increased further, with PsV GMT reaching 1,862Vaccination also led to a significant increase in T-cell response (mainly Th1 CD4 T cells)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
